Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaera, a biopharmaceutical company, has reported that its development partner MedImmune presented interim Phase IIa data on MEDI-528, its monoclonal antibody targeting interleukin-9 in adults with mild, persistent asthma.
Subscribe to our email newsletter
MedImmune reported the absence of serious, dose-limiting adverse events in the study and concluded that the data also demonstrated an acceptable safety profile for multiple subcutaneous doses of MEDI-528.
Interleukin-9 (IL-9) is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-9 in animal models has been shown to result in many features of asthma, including increased airway inflammation and hyperreactivity.
MedImmune is conducting research to evaluate the potential to use monoclonal antibodies targeting IL-9 to treat or prevent symptomatic, moderate-to-severe, persistent asthma.